Schizophrenia Trial, Recruiting NCT07434479 Sponsor: Manhattan Psychiatric Center Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07434479
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give written consent to take part, attend study visits, and follow study-related requirements
  • People who are fluent in written and spoken English, confirmed by being able to read and understand the consent form
  • People who are currently on a stable dose of atypical antipsychotic medication, with no changes to that medication in the 2 weeks before enrolling
  • People who have a documented record of taking their medication as prescribed for the 2 weeks before enrolling, with no missed doses, as confirmed by medical records
  • People who have a history of impulsive aggression, as shown by a qualifying score on a specific aggression assessment scale (the IPAS)
  • People who have adequate vision and hearing to complete study assessments and engage with virtual reality content
  • People with a primary diagnosis of schizophrenia or schizoaffective disorder, confirmed using a structured clinical interview (the SCID-5-RV) at the screening visit
  • People aged between 18 and 64 years at the time of giving consent

Who may not be able to join:

  • People with a history of head trauma
  • People who have been diagnosed with a neurological disorder
  • People who are pregnant or breastfeeding, as recorded in their medical records
  • People with an unstable medical condition that could affect their safety during the study
  • People who are experiencing significant thoughts of suicide at screening, specifically those who answer "yes" to certain items on a standardised suicide assessment scale (the C-SSRS), indicating active suicidal thoughts with some intent or a specific plan
  • People who have received electroconvulsive therapy (ECT) within 6 months of the study, or who have metal implants in their body, or who experience claustrophobia, or who do not pass the site's MRI safety screening questionnaire
  • People who do not meet the minimum score for impulsive aggression on the IPAS assessment scale
  • People who have had a violent episode in the week before screening that required seclusion, physical restraints, or emergency medication
  • People whose medication records show poor adherence in the 2 weeks before enrolling, including two or more missed doses, or blood levels suggesting the intended therapeutic dose is not being received

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anzalee Khan, PhD, Nathan Kline Institute for Psychiatric Research

Phone: 646-766-5876

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Manhattan Psychiatric Center
Registry
ClinicalTrials.gov
Start date
5 June 2026
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Short UPPS-P Impulsive Behavior Scale; Impulsive-Premeditated Aggression Scale; Positive and Negative Syndrome Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov